NL-OMON43374已完成4 期
MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES. - PLEIADES-pcsk9
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age of 18 years or older
- •- Fasting triglycerides levels between 1.8 mmol/L and 7.0 mmol/L
- •- Diabetes mellitus type 2 on intensive insulin treatment (three times short acting and one daily long acting) (unchanges for >10 weeks prior to consent)
- •- Stable glucose regulation last 6 months (HbA1c >6.5% - < <9.0%)
- •- Stable lipid lowering therapy last 2 months (no changes in regiments or dose)
排除标准
- •- Current smoking
- •- Impaired renalfunction (MDRD <60 ml/min/1.73 m2)
- •- Recent cardiovascular event (<6 months) (myocardial infarction, coronary artery bypass grafting, stroke)
- •- Severe hyperglycemic events in the past 6 months (hyperglycemia >20 mmol/L requiring hospital admittance)
- •- Recent or current use of pcsk9 antibodies
- •- HIV-infection
- •- Uncontrolled hypothyroidism
研究者
相似试验
进行中（未招募）
1 期
Influence of a new medicine on cholesterol and other factors after intake of a meal in patients with diabetesDiabetes mellitus type 2EUCTR2016-003253-15-NLFranciscus Gasthui
尚未招募
不适用
Postprandial effects of alirocumab on lipemia and inflammtioNL-OMON22535Franciscus Gasthuis20
进行中（未招募）
1 期
Influence of a new diabetesmedicine on cholesterol and other factors after intake of a fatty meal in patients with diabetesDiabetes Mellitus type IIEUCTR2016-001417-24-NLFranciscus Gasthuis
尚未招募
不适用
Postprandial effects of dapagliflozin on lipemia and inflammatioType 2 Diabetes MellitusNL-OMON21590Franciscus Gasthuis, Rotterdam20
已完成
4 期
Postprandial Lipemia, Inflammation, and Vascular Function in Diabetes modulated by dapaglifloziAtherosclerosepostmeal fat influence100184241001331710003216NL-OMON46285Sint Franciscus Gasthuis14